Cezanne™ Integrated Cell/Antibody Therapeutic Systems

Product Description

CezanneTM couples current monoclonal antibody therapeutics with the emerging cell therapy technologies by introducing engineered antibodies that specifically and uniquely pair with MonetTM modified cell lines eliminating innate molecule competition and reducing dose requirements. Progenitor’s revolutionary CezanneTM technology allows cellular therapies to more efficiently target solid tumors, as well as, hematological malignancies.